Press release
Nov 29, 2024  ·  Regulatory information

Cantargia expands the CAN10 phase 1 clinical program building on positive results

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported initiation of an expanded part of CAN10’s phase 1 clinical study to investigate higher dose levels of the antibody. The purpose of this expansion is to build on the good safety, potent effects on biomarkers and pharmacokinetic properties of CAN10. Current data indicate durable effects and potential for treatment every 4th week, which will be a competitive advantage. The first participant in this program has now been dosed.

The accrued CAN10 clinical results underscore the potential for dosing every 4th week. This is a competitive advantage, therefore the ongoing phase 1 clinical trial is expanded to obtain additional results before the planned start of phase 2 during H2 2025”, said Göran Forsberg, CEO of Cantargia.

CAN10 is an antibody against IL1RAP, designed to potently inhibit the activity of the pro-inflammatory and disease promoting cytokines IL-1, IL-33 and IL-36. CAN10 is currently examined in a phase 1 clinical trial with the primary goal to investigate safety. So far, healthy participants have been treated in 9 single ascending dose (SAD) cohorts and the first multiple ascending dose (MAD) cohort in participants with mild to moderate plaque psoriasis is ongoing. No safety concerns have been reported and biomarker studies confirm binding to immune cells like neutrophils and monocytes as well as complete inhibition of IL-1 and IL-36 stimulation.

The results obtained indicate that CAN10 has long-lasting effects that would allow dosing every 4th week, while several other antibodies use more frequent dosing. To further document this potential competitive advantage e.g. leading to improved patient convenience, the clinical protocol has been amended to allow up to two additional SAD cohorts as well as up to two additional MAD cohorts in healthy participants. The first participant in this new part of the trial has been dosed. The plan is to perform these activities during the upcoming months in line with the plan to start phase 2 during H2 2025.